drugset
drugset / Trial / NCT04160091

Study to Evaluate the Efficacy and Safety of FX006 in Patients With Glenohumeral Osteoarthritis or Shoulder Adhesive Capsulitis

NCT04160091 ↗

Phase 2 Terminated 19 enrolled Pacira Pharmaceuticals, Inc Medpace, Inc. · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a double-blind study to evaluate the efficacy and safety of FX006 in patients with glenohumeral osteoarthritis (OA) or shoulder adhesive capsulitis (AC).

Timeline

Start
2019-11-07
Primary completion
2020-06-15
Completion
2020-06-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Tafamidis Unknown 32 mg Other

Indications

frozen shoulder osteoarthritis